RCKT Valuation

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

RCKT Relative Valuation

RCKT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RCKT is overvalued; if below, it's undervalued.

Historical Valuation

Rocket Pharmaceuticals Inc (RCKT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 17.63 is considered Undervalued compared with the five-year average of 710.42. The fair price of Rocket Pharmaceuticals Inc (RCKT) is between 17.98 to 40.82 according to relative valuation methord. Compared to the current price of 8.01 USD , Rocket Pharmaceuticals Inc is Undervalued By 55.45%.

Relative Value

Fair Zone

17.98-40.82

Current Price：8.01

55.45%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.84

P/B

Median3y

3.58

Median5y

4.13

-25.72

FCF Yield

Median3y

-14.03

Median5y

-11.13

Competitors Valuation Multiple

The average P/S ratio for RCKT's competitors is 78.06, providing a benchmark for relative valuation. Rocket Pharmaceuticals Inc Corp (RCKT) exhibits a P/S ratio of 17.63, which is -77.41% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

RCKT.O

Rocket Pharmaceuticals Inc

17.63

Average P/S: 78.06

855.35M